SLC6A3 and Parkinson disease: Several studies, using 123-I-beta-CIT SPECT, demonstrated reduced dopamine transporter binding in the caudate and posterior putamen in DLB compared to AD patients (13, 14), but no difference between DLB and Parkinson’s Disease (PD) patients.